vs
Indivior Pharmaceuticals, Inc.（INDV）与Mativ Holdings, Inc.（MATV）财务数据对比。点击上方公司名可切换其他公司
Mativ Holdings, Inc.的季度营收约是Indivior Pharmaceuticals, Inc.的1.3倍（$463.1M vs $357.0M），Indivior Pharmaceuticals, Inc.净利率更高（28.9% vs 21.8%，领先7.1%），Mativ Holdings, Inc.自由现金流更多（$8.0M vs $-245.0M）
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
INDV vs MATV — 直观对比
营收规模更大
MATV
是对方的1.3倍
$357.0M
净利率更高
INDV
高出7.1%
21.8%
自由现金流更多
MATV
多$253.0M
$-245.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $357.0M | $463.1M |
| 净利润 | $103.0M | $100.8M |
| 毛利率 | 82.1% | 18.8% |
| 营业利润率 | 22.7% | 2.2% |
| 净利率 | 28.9% | 21.8% |
| 营收同比 | — | 1.0% |
| 净利润同比 | 390.5% | 6620.0% |
| 每股收益（稀释后） | $0.79 | $1.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDVMATV
| Q4 25 | $357.0M | $463.1M | ||
| Q3 25 | $314.0M | $513.7M | ||
| Q2 25 | $302.0M | $525.4M | ||
| Q1 25 | $266.0M | $484.8M | ||
| Q4 24 | — | $458.6M | ||
| Q3 24 | $307.0M | $498.5M | ||
| Q2 24 | $299.0M | $523.8M | ||
| Q1 24 | — | $500.2M |
净利润INDVMATV
| Q4 25 | $103.0M | $100.8M | ||
| Q3 25 | $42.0M | $-3.2M | ||
| Q2 25 | $18.0M | $-9.5M | ||
| Q1 25 | $47.0M | $-425.5M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $22.0M | $-20.8M | ||
| Q2 24 | $-97.0M | $-1.4M | ||
| Q1 24 | — | $-28.0M |
毛利率INDVMATV
| Q4 25 | 82.1% | 18.8% | ||
| Q3 25 | 73.2% | 19.3% | ||
| Q2 25 | 82.8% | 19.7% | ||
| Q1 25 | 83.1% | 15.0% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | 78.5% | 18.8% | ||
| Q2 24 | 73.6% | 20.8% | ||
| Q1 24 | — | 16.8% |
营业利润率INDVMATV
| Q4 25 | 22.7% | 2.2% | ||
| Q3 25 | 13.7% | 3.1% | ||
| Q2 25 | 23.8% | 3.8% | ||
| Q1 25 | 24.8% | -88.8% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | 11.4% | 1.4% | ||
| Q2 24 | -39.5% | 2.0% | ||
| Q1 24 | — | -2.8% |
净利率INDVMATV
| Q4 25 | 28.9% | 21.8% | ||
| Q3 25 | 13.4% | -0.6% | ||
| Q2 25 | 6.0% | -1.8% | ||
| Q1 25 | 17.7% | -87.8% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 7.2% | -4.2% | ||
| Q2 24 | -32.4% | -0.3% | ||
| Q1 24 | — | -5.6% |
每股收益（稀释后）INDVMATV
| Q4 25 | $0.79 | $1.87 | ||
| Q3 25 | $0.33 | $-0.06 | ||
| Q2 25 | $0.14 | $-0.18 | ||
| Q1 25 | $0.38 | $-7.82 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | $0.16 | $-0.38 | ||
| Q2 24 | $-0.72 | $-0.03 | ||
| Q1 24 | — | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.0M | $84.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $-98.0M | $498.7M |
| 总资产 | $1.2B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资INDVMATV
| Q4 25 | $195.0M | $84.2M | ||
| Q3 25 | $445.0M | $97.1M | ||
| Q2 25 | $510.0M | $95.6M | ||
| Q1 25 | $373.0M | $84.0M | ||
| Q4 24 | — | $94.3M | ||
| Q3 24 | — | $162.2M | ||
| Q2 24 | — | $133.4M | ||
| Q1 24 | — | $128.9M |
总债务INDVMATV
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
股东权益INDVMATV
| Q4 25 | $-98.0M | $498.7M | ||
| Q3 25 | $-207.0M | $397.4M | ||
| Q2 25 | $-257.0M | $416.6M | ||
| Q1 25 | $-285.0M | $428.2M | ||
| Q4 24 | — | $858.5M | ||
| Q3 24 | $-310.0M | $882.3M | ||
| Q2 24 | $-281.0M | $898.0M | ||
| Q1 24 | — | $906.9M |
总资产INDVMATV
| Q4 25 | $1.2B | $2.1B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $1.4B | $2.1B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.7B |
负债/权益比INDVMATV
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 1.30× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-221.0M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $-245.0M | $8.0M |
| 自由现金流率自由现金流/营收 | -68.6% | 1.7% |
| 资本支出强度资本支出/营收 | 6.7% | 2.4% |
| 现金转化率经营现金流/净利润 | -2.15× | 0.19× |
| 过去12个月自由现金流最近4个季度 | $-93.0M | $93.8M |
8季度趋势，按日历期对齐
经营现金流INDVMATV
| Q4 25 | $-221.0M | $19.3M | ||
| Q3 25 | $-39.0M | $72.8M | ||
| Q2 25 | $158.0M | $57.6M | ||
| Q1 25 | $75.0M | $-15.9M | ||
| Q4 24 | — | $24.1M | ||
| Q3 24 | $2.0M | $37.6M | ||
| Q2 24 | $88.0M | $46.1M | ||
| Q1 24 | — | $-13.0M |
自由现金流INDVMATV
| Q4 25 | $-245.0M | $8.0M | ||
| Q3 25 | $-59.0M | $66.7M | ||
| Q2 25 | $141.0M | $48.9M | ||
| Q1 25 | $70.0M | $-29.8M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | $-5.0M | $25.5M | ||
| Q2 24 | $84.0M | $37.4M | ||
| Q1 24 | — | $-25.1M |
自由现金流率INDVMATV
| Q4 25 | -68.6% | 1.7% | ||
| Q3 25 | -18.8% | 13.0% | ||
| Q2 25 | 46.7% | 9.3% | ||
| Q1 25 | 26.3% | -6.1% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -1.6% | 5.1% | ||
| Q2 24 | 28.1% | 7.1% | ||
| Q1 24 | — | -5.0% |
资本支出强度INDVMATV
| Q4 25 | 6.7% | 2.4% | ||
| Q3 25 | 6.4% | 1.2% | ||
| Q2 25 | 5.6% | 1.7% | ||
| Q1 25 | 1.9% | 2.9% | ||
| Q4 24 | — | 4.8% | ||
| Q3 24 | 2.3% | 2.4% | ||
| Q2 24 | 1.3% | 1.7% | ||
| Q1 24 | — | 2.4% |
现金转化率INDVMATV
| Q4 25 | -2.15× | 0.19× | ||
| Q3 25 | -0.93× | — | ||
| Q2 25 | 8.78× | — | ||
| Q1 25 | 1.60× | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
